NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) — Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions for delivery in proprietary digitally connected devices, announced the appointments of Jamel Benkreira as General Manager, United Kingdom & Ireland; and Dr. Pallav S. Shah as Director of Regulatory Affairs, Europe. These strategic appointments strengthen the Company’s international leadership team as the Company continues to expand its liquid oral suspension portfolio and global market presence.
“The addition of Mr. Benkreira and Dr. Shah following our recent of appointments of Alvaro Fernandez and Marc Van Unen as General Managers, Spain and Germany, respectively, is a deliberate expansion of our global capabilities at a critical inflection point,” said Michael Demurjian, Chief Executive Officer & Chairman of Aspargo Labs. “Mr. Benkreira’s successful commercialization and sales record in challenging international markets and Dr. Shah’s proven regulatory expertise with complex regulatory submissions directly align with our immediate priorities: accelerating significant sales growth and commercializing oral liquid suspensions in major international markets.”
Mr. Benkreira joins Aspargo Labs with over 22 years of international experience leading commercial teams and launching products across global markets outside the U.S. Before joining Aspargo, Mr. Benkreira held several key positions at Pharming, NV. including Head of Europe, Middle East, and Africa, where he led business strategy for the launch of a rare disease product in the region. His career includes roles at Bristol-Myers Squibb, GlaxoSmithKline, ViiV Healthcare, Pfizer, and Aimmune Therapeutics. He has managed products through their full lifecycle, from pre-clinical development to commercialization, market expansion, and loss of exclusivity. His expertise spans multiple therapeutic areas, including cardiovascular disease, mental health, oncology, respiratory conditions, HIV, peanut allergy and rare diseases. Mr. Benkreira holds a BSc in Biochemistry & Genetics from the University of Leeds, United Kingdom.
Dr. Shah brings extensive expertise in regulatory affairs, pharmacovigilance, and medicinal chemistry to Aspargo Labs. Previously, Dr. Shah served as Chief Executive Officer of Cambridge Regulatory Services, where he oversaw regulatory strategy, pharmacovigilance operations, and medical information services. His experience includes managing marketing authorization applications, clinical trial applications, risk-benefit assessments, and ensuring adherence to international regulatory standards. At Cambridge Regulatory services, Dr. Shah successfully obtained marketing authorizations for over 30 products in multiple countries. Dr. Shah holds a Ph.D. in Medicinal Chemistry from the University of the West of Scotland, where his research focused on the synthesis and evaluation of novel compounds for the treatment of hormone-dependent breast cancer. He also earned an MSc in Pharmaceutical Science from Kingston University and a B. Pharm in Pharmaceutical Science from Mumbai University.
About Aspargo Labs, Inc.
Aspargo Labs, Inc., is a specialty pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions delivered via a proprietary, digitally connected device. Aspargo Labs’ suspension technology offers several key advantages, including improved absorption, ease of administration, flexible dosing, and improved patient adherence. Aspargo is leveraging its unique technology platform to transform a wide range of medications across various therapeutic areas. The initial focus is a liquid oral sildenafil suspension currently marketed by Aspargo in multiple countries.
For additional information, please visit our website at www.aspargolabs.com.
FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; and the outcome of pending or future litigation or arbitration.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.
For more information:
Aspargo Labs, Inc.
(646) 503-1260
[email protected]
Investor & media contacts:
Russo Partners
Nic Johnson or Liz Phillips
(347) 956-7697
[email protected]
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/7ebaa7bb-d6c0-46a5-a9e8-fd80a244bdfd
https://www.globenewswire.com/NewsRoom/AttachmentNg/68201776-8b3a-479d-906c-3a1a224e6fa3
